What are the preparation steps for administering pasireotide (Signifor) long‑acting release (LAR) injection?

Preparation Steps for Signifor LAR Administration

Prior to administering pasireotide long-acting release (LAR), you must obtain baseline laboratory values including fasting plasma glucose, HbA1c, liver function tests, serum potassium and magnesium levels, perform a baseline ECG, and obtain a gallbladder ultrasound 1.

Pre-Administration Laboratory and Diagnostic Requirements

Mandatory Baseline Testing

Before initiating Signifor LAR, the following assessments are required 1:

• Fasting plasma glucose (FPG) and HbA1c - Critical given the high risk of hyperglycemia (57% of patients develop hyperglycemia-related adverse events) 2
• Liver function tests - Required for monitoring hepatotoxicity risk
• Serum potassium and magnesium levels - Essential due to QT prolongation risk
• Baseline electrocardiogram (ECG) - Mandatory to assess for pre-existing cardiac conduction abnormalities
• Gallbladder ultrasound - Required as gallstones occur in approximately 25% of patients on somatostatin receptor ligands 2

Critical Pre-Treatment Optimization

For patients with poorly controlled diabetes mellitus (HbA1c >8%), you must intensively optimize anti-diabetic therapy BEFORE starting Signifor 1. This is non-negotiable, as these patients face higher risk of severe hyperglycemia and associated complications including ketoacidosis 1.

Reconstitution and Preparation Steps

For LAR Formulation (Intramuscular)

The LAR formulation requires reconstitution before intramuscular injection, unlike the ready-to-use subcutaneous formulations 3. This is a key distinction from lanreotide formulations which come pre-filled.

For Subcutaneous Formulation

The subcutaneous formulation comes in single-dose ampules 1:

1. Inspect the ampule - Verify it is not cracked or broken; liquid must be clear and colorless 1
2. Check dose and expiration date on the ampule 1
3. Tap the ampule top to ensure no liquid remains in the upper portion 1
4. Open ampule just prior to administration - Any unused portion must be discarded 1
5. Snap off ampule top at the marked line on the neck 1
6. Draw up medication using appropriate sterile needle and syringe 1
7. Remove air bubbles by tapping syringe and pushing plunger until a drop appears at needle tip 1

Injection Site Preparation

• Wipe injection site with alcohol and allow to dry 1
• Avoid sites with inflammation or irritation 1
• Do not use the same injection site for 2 consecutive injections 1
• For subcutaneous administration: inject into top of thigh or abdomen at a 45-degree angle 1
• For LAR: administer via deep intragluteal intramuscular injection 4

Special Considerations for Hepatic Impairment

For patients with moderate hepatic impairment (Child-Pugh B), reduce the initial dose to 0.3 mg twice daily with a maximum of 0.6 mg twice daily 1. Avoid Signifor entirely in severe hepatic impairment (Child-Pugh C) 1.

Common Pitfalls to Avoid

• Do not skip the baseline gallbladder ultrasound - While routine monitoring ultrasounds are not recommended 2, the baseline is mandatory per FDA labeling 1
• Do not start Signifor in patients with uncontrolled diabetes without first optimizing their glycemic control 1
• Do not confuse LAR with subcutaneous formulations - LAR requires reconstitution and intramuscular administration, while subcutaneous comes ready-to-use 3
• Do not reuse injection sites consecutively - This increases local adverse reactions 1

The evidence strongly emphasizes that hyperglycemia management is the most critical safety concern, with pasireotide causing significantly more hyperglycemic events (57.3%) compared to octreotide (21.7%) 5. The pre-treatment optimization and baseline assessments are designed to identify and mitigate these risks before they become clinically significant.